These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10573047)

  • 21. Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia.
    Hopkins TM; Juang P; Weaver K; Kollef MH; Betthauser KD
    Clin Ther; 2019 Dec; 41(12):2540-2548. PubMed ID: 31676040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project.
    Frei CR; Koeller JM; Burgess DS; Talbert RL; Johnsrud MT
    Pharmacotherapy; 2003 Sep; 23(9):1167-74. PubMed ID: 14524648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Community-acquired pneumonia team decreases length of stay in hospitalized, low-risk patients with pneumonia.
    Marcos PJ; Restrepo MI; Sanjuàn P; Ferreira-Gonzalez L; Verea-Hernando H
    Hosp Pract (1995); 2013 Aug; 41(3):7-14. PubMed ID: 23948616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
    Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
    J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?
    Cunha BA
    Chest; 2004 May; 125(5):1913-9. PubMed ID: 15136407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.
    Wilson BZ; Anzueto A; Restrepo MI; Pugh MJ; Mortensen EM
    Crit Care Med; 2012 Aug; 40(8):2310-4. PubMed ID: 22622401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
    Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
    BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of macrolide in treating adult hospitalized community-acquired pneumonia.
    Loh LC; Quah SY; Khoo SK; Vijayasingham P; Thayaparan T
    Respirology; 2005 Jun; 10(3):371-7. PubMed ID: 15955152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
    Weiss K; Tillotson GS
    Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
    Dresser LD; Niederman MS; Paladino JA
    Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing and developing strategies for the treatment of community-acquired pneumonia at a community hospital.
    Fok MC; Kanji Z; Mainra R; Boldt M
    Can Respir J; 2002; 9(4):247-52. PubMed ID: 12195270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
    N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
    Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
    Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical pathway for community-acquired pneumonia: an observational cohort study.
    Frei CR; Bell AM; Traugott KA; Jaso TC; Daniels KR; Mortensen EM; Restrepo MI; Oramasionwu CU; Ruiz AD; Mylchreest WR; Sikirica V; Raut MR; Fisher A; Schein JR
    BMC Infect Dis; 2011 Jul; 11():188. PubMed ID: 21733161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.